share_log

ESSA Pharma Slides As Insider Purchases Lose Another US$211k

ESSA Pharma Slides As Insider Purchases Lose Another US$211k

essa pharma股價下跌,內部人士購買減少21.1萬美元
Simply Wall St ·  11/04 22:18

Insiders who bought US$289.3k worth of ESSA Pharma Inc.'s (NASDAQ:EPIX) stock at an average buy price of US$5.17 over the last year may be disappointed by the recent 74% decrease in the stock. This is not good as insiders invest based on expectations that their money will appreciate over time. However, as a result of recent losses, their original investment is now worth only US$78.4k.

在過去一年裏,買入essa pharma股票總價值28.93萬美元,平均購入價爲5.17美元的內部人士,可能對股價最近下跌74%感到失望。內部人士根據對錢財會隨時間增值的預期而投資,但由於最近的虧損,他們的原始投資現在僅值7.84萬美元。

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.

雖然我們永遠不會建議投資者僅基於公司董事已經做出的決策而做出決策,但同時我們認爲完全忽略內部交易是愚蠢的。

ESSA Pharma Insider Transactions Over The Last Year

過去一年中,essa pharma內部交易

In the last twelve months, the biggest single purchase by an insider was when Independent Director Franklin Berger bought US$135k worth of shares at a price of US$5.73 per share. That means that an insider was happy to buy shares at above the current price of US$1.40. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

在過去十二個月中,內部人士中最大的單筆購買是獨立董事Franklin Berger以5.73美元每股的價格購入價值13.5萬美元的股票。這意味着內部人士樂意以高於當前價格1.40美元購買股票。他們很可能後悔購買,但更可能是對該公司看好。對我們來說,考慮內部人員購買股票的價格非常重要。一般來說,當內部人員以高於當前價格購入股票時,我們會着眼,因爲這表明他們認爲這些股票值得購買,即使價格更高。

ESSA Pharma insiders may have bought shares in the last year, but they didn't sell any. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

essa pharma內部人士可能在過去一年裏購買了股票,但他們沒有賣出任何股票。您可以在下面的圖表中看到內部交易(由公司和個人)在過去一年的情況。點擊下面的圖表,您可以看到每筆內部交易的詳細信息!

big
NasdaqCM:EPIX Insider Trading Volume November 4th 2024
納斯達克CM:EPIX內幕交易量2024年11月4日

ESSA Pharma is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

essa pharma並非唯一一家內部人員在購買股票的公司。對於那些喜歡找到估值吸引人的小盤公司的人,這份最新內部人員購買的增長型公司免費名單可能正合你意。

Insider Ownership Of ESSA Pharma

essa pharma內部持股

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data suggests ESSA Pharma insiders own 2.2% of the company, worth about US$1.4m. I generally like to see higher levels of ownership.

查看一家公司內部人員的總持股量,有助於判斷他們與普通股東的是否利益一致。高比例的內部持股往往使公司領導更加關注股東利益。我們的數據顯示,essa pharma的內部人員擁有公司2.2%的股份,價值約140萬美元。我通常希望看到更高比例的持股。

So What Do The ESSA Pharma Insider Transactions Indicate?

那麼,essa pharma內部交易究竟意味着什麼?

There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. We'd like to see bigger individual holdings. However, we don't see anything to make us think ESSA Pharma insiders are doubting the company. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 4 warning signs for ESSA Pharma (of which 2 shouldn't be ignored!) you should know about.

過去三個月內沒有任何內部交易——這並沒有太大意義。值得一提的是,過去一年的交易情況令人鼓舞。我們希望看到更大的個人持股。但是,我們並沒有發現任何跡象表明essa pharma的內部人員對公司存疑。因此,了解內部人員是在買入還是賣出固然有幫助,但了解特定公司面臨的風險也是很有幫助的。每家公司都存在風險,而我們已經發現essa pharma存在4個警示信號(其中有2個不容忽視!)你應該知道的。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果您想查看另一家公司的信息-一家潛在具有優秀財務狀況的公司-請不要錯過這個帶有高股權回報率和低債務的有趣公司免費列表。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論